Fidelity Select Pharmaceuticals EBIT

As of the most recent data (September 2023), FPHAX shows a EBIT of $-1.4M. That compares with $-23M in the prior-year period — up 93.6% year over year. That is above the sector sector average of $-25M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FPHAX's EBIT is now $-1.4M (was $-23M) — a 93.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Fidelity Select Pharmaceuticals is outperforming or lagging.

The its sector sector average EBIT is about $-25M. Fidelity Select Pharmaceuticals is at $-1.4M, which is higher that average. That is roughly 94.3% above the sector mean. Use the comparison chart on this page to see how FPHAX stacks up against individual peers as well.

Tracking FPHAX's ebit over time shows whether Fidelity Select Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-1.4M That compares with $-23M in the prior-year period — up 93.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Fidelity Select Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-1.4M) with ownership activity and broader fundamentals.